Skip to main content

Table 2 Heart failure outcome trials completed in 2021: comparison of active vs. placebo group

From: Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes

EMPEROR-preserved [37]
Class and cardiovascular outcomes HR (95% CI) p-value
Primary composite outcome
 Composite of cardiovascular death or hospitalization for heart failure 0.79 (0.69–0.90) < 0.001
Secondary outcome
 Total number of hospitalizations for heart failure 0.73 (0.61–0.88) < 0.001
Secondary outcome
 Mean slope of change in eGFR per year—ml/min/1.73 m2 1.36 (1.06–1.66) < 0.001
Other prespecified analyses
 Change in KCCQ clinical summary score at week 52 1.32 (0.45–2.19)  
Other prespecified analyses
 Total number of hospitalizations for any cause 0.93 (0.85–1.01)  
Other prespecified analyses
 Composite renal outcome 0.95 (0.73–1.24)  
Other prespecified analyses
 Onset of new diabetes in patients with prediabetes 0.84 (0.65–1.07)  
Other prespecified analyses
 Death from any cause 1.00 (0.87–1.15)  
Adverse events Event rate (%) active vs. placebo group  
Urinary tract infections 9.9 vs. 8.1  
Genital infections 2.2 vs. 0.7  
Hypotension 10.4 vs. 8.6  
  1. KCCQ Kansas City Cardiomyopathy Questionnaire